Your institution may have access to this item. Find your institution then sign in to continue.
Title
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Authors
Lee, W J; Lee, J L; Chang, S E; Lee, M W; Kang, Y K; Choi, J H; Moon, K C; Koh, J K
Abstract
The multitargeted kinase inhibitors sorafenib and sunitinib have improved treatment of solid tumours including renal cell carcinoma and hepatocellular carcinoma by offering better clinical responses. However, sorafenib and sunitinib are commonly associated with cutaneous toxicity.
Publication
The British journal of dermatology, 2009, Vol 161, Issue 5, p1045